MapLight Therapeutics Raises $372.5M in Series D
MapLight Therapeutics has successfully raised $372.5M in a Series D led by Forbion, Goldman Sachs Alternatives.
Company Overview
MapLight Therapeutics is a HealthTech company headquartered in Redwood City, CA, founded in 2018 with 150+ employees.
Biopharma company developing medicines for brain disorders using novel drug discovery platform
Fundraising Details
- Amount Raised: $372.5M
- Round Type: Series D
- Date: 2025-09-29
- Investors: Forbion, Goldman Sachs Alternatives
About MapLight Therapeutics
Biopharma company developing medicines for brain disorders using novel drug discovery platform The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: Redwood City, CA
- Founded: 2018
- Team Size: 150+
- Industry: HealthTech
What This Means
This funding round demonstrates strong investor confidence in MapLight Therapeutics's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. MapLight Therapeutics's successful fundraising reflects the strong fundamentals and growth potential in this space.
Looking Ahead
With this new capital, MapLight Therapeutics is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
---
This fundraising news was reported on 2025-09-29. For more information about MapLight Therapeutics, visit their headquarters at Redwood City, CA.
